HLS Therapeutics And Amarin To Present IPE And EPA Mechanistic Effects At Canadian Cardiovascular Congress 2025

Author: Benzinga Newsdesk | October 14, 2025 07:48am

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, in collaboration with its partner, Amarin Corporation plc (NASDAQ:AMRN) announce the presentation of scientific data at the upcoming Canadian Cardiovascular Congress ("CCC") in Quebec City, from October 23 to 26, 2025. These presentations reflect the continued commitment of HLS and Amarin to advancing the broader therapeutic potential of Icosapent Ethyl ("IPE") and Eicosapentaenoic Acid ("EPA"), further highlighting their dedication to improving cardiovascular care for appropriate at-risk patients.

Data to be presented at CCC 2025 highlights the clinical value of IPE for cardiometabolic conditions as well as the further attempts to explore the mechanistic effects of EPA on atherogenic lipoproteins and in endothelial cells during inflammation when combined with a GLP-1 receptor agonist.

Posted In: AMRN TSX:HLS